Navigation Links
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:8/31/2007

SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 6, 2007 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview of the company and its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2020)... ... March 20, 2020 , ... My heart goes out ... from COVID-19. Having also lost a loved one recently through similar circumstances - underlying ... few days, I have felt a gamut of negative emotions just like many have: ...
(Date:3/20/2020)... ... March 20, 2020 , ... The ... team of researchers in machine learning, bioinformatics, immunology, virology and vaccine design to ... outbreaks. , "The COVID-19 crisis gives us an opportunity and a profound motivation ...
(Date:3/19/2020)... ... 19, 2020 , ... Therapies of The Rockies has Colorado’s back, and they ... welcome new telepractice patients across the country, as remote therapy services have no geographic ... or resume your services safely! , Therapies of The Rockies is a Denver-area speech, ...
(Date:3/19/2020)... ... March 19, 2020 , ... ... to teach Executive Function, shares a free Student Learning Exercise: ExQ® Superpower ... parents and teachers are seeking resources to help with the immediate need for ...
(Date:3/19/2020)... ... March 19, 2020 , ... Van Dyk Health Care, which ... of Caring, on October 3, 2018 and is not involved in the operations of ... involving Family of Caring at Montclair. , “We are devastated to learn about the ...
Breaking Medicine News(10 mins):
(Date:3/30/2020)... ... March 30, 2020 , ... “In the time of remote ... hear stories from our customers of vendor price-gouging. We are here to promise ... hardships in this difficult time,” says Borya Shakhnovich, CEO of airSlate -- parent ...
(Date:3/30/2020)... ... March 30, 2020 , ... In order to ... telemedicine appointments in addition to in-person visits. The San Diego-based leader in ... of patients, health care professionals, and the community at large is the top ...
(Date:3/28/2020)... (PRWEB) , ... March 27, 2020 , ... Known for ... Wendy May Real has launched a new hand sanitizer in response to the COVID-19 ... hand sanitizer market will continue to expand during the next several months even in ...
Breaking Medicine Technology: